Current and future trends in the oral pharmacotherapy of male erectile dysfunction

Bibliography

• KANDEEL FR, KOUSSA VKT, SWERDLOFF RS: Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocrine Rev (2001) 22:342–388.
   PubMed Web of Science ®Google Scholar
• AYTA IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br. J. Urol. (1999) 84:50–56.
   Google Scholar
• HOLMQUIST F, STIEF CG, JONAS U, ANDERSSON K-E: Effects of the nitric oxide synthase inhibitor Nc-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand. (1991) 143:299–304.
   PubMedGoogle Scholar
• HOLMQUIST F, HEDLUND H, ANDERSSON K-E: NG-Nitro-L-arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol Scand. (1991) 141:441–442.
   PubMedGoogle Scholar
• IGNARRO LJ, BUSH PA, BUGA GM, WOODS KS, FUKUTO JM, RAJFER J: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochein. Biophys. Res. Comm. (1990) 170:843–850.
   PubMed Web of Science ®Google Scholar
• ANDERSSON K-E, WAGNER G: Physiology of penile erection. Pharmacol Rev (1995) 75:191–236.
   Google Scholar
• ANDERSSON K-E, HOLMQUIST F: Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J. Urol. (1994) 12:249–261.
   PubMed Web of Science ®Google Scholar
• LINCOLN TM, CORNWELL TL: Intracellular cyclic GMP receptor proteins. FASEB J. (1993) 7:328–338.
   PubMed Web of Science ®Google Scholar
• POZZAN T, RIZUTTO R, VOLPE P, MELDOLESI J: Molecular and cellular physiology of intracellular calcium stores. Physiol Rev (1994) 74:595–636.
   PubMed Web of Science ®Google Scholar
• TRUSS MC, BECKER AJ, DJAMILLIAN MH, STIEF CG, JONAS U: Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology (1994) 44:553–556.
   PubMed Web of Science ®Google Scholar
• HEATON JP, MORALES A, OWEN J: Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. Urol. (1990) 143:729–731.
   Web of Science ®Google Scholar
• OCKERT S, KOTHE A, STIEF CG, JONAS U: Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J. Urol. (2001) 19:14-22 (2001).
   Google Scholar
• PORST H: The rationale for prostaglandinEl in erectile failure: a survey of worldwide experience. Urol. (1996) 155:802–815.
   Web of Science ®Google Scholar
• OTTENSEN B, WAGNER G, VIRAG R, FAHRENKRUG J: Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br. J. Med. (1984) 288:9–11.
   PubMed Web of Science ®Google Scholar
• CAHN D, MELMAN A, VALCIC M, CHRIST GJ: Forskolin: a promising new adjunct to intracavernous pharmacotherapy. Urol. (1997) 155:1789–1794.
   Web of Science ®Google Scholar
• HALL IP: Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br. J. Clin. Pharmacol (1993) 35:1–7.
   PubMed Web of Science ®Google Scholar
• ROTELLA P: Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. (2002) 1:674–682.
   PubMed Web of Science ®Google Scholar
• CONTI M, JIN SL: The molecular biologyof cyclic nucleotide phosphodiesterases. Frog. Nucleic Acid Res. Ma Biol. (1999) 63:1–38.
   PubMed Web of Science ®Google Scholar
• SODERLING SH, BEAVO JA: Regulationof cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. (2000) 12:174–179.
   PubMed Web of Science ®Google Scholar
• TAHER A, STIEF CG, RAIDA M, JONAS U, FORSSMANN WG: Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int. J. Impot. Res. (1992) 4\(Suppl. 2):11.
   Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD S et al: Sildenafil: an orally active Type 5 cGMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J Impot. Res. (1996) 8:47–52.
   PubMedGoogle Scholar
• KOTHE A, WIEDENROTH A, MAGERT HJ et al: Expression of different phosphodiesterase genes in human cavernous smooth muscle. Urol. (2001) 165:280–283.
   Web of Science ®Google Scholar
• BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. Urol. (1998) 159:2164–2171.
   Web of Science ®Google Scholar
• GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction. N Engl. Med. (1998) 338:1397–1404.
   PubMed Web of Science ®Google Scholar
• BROCK G: Sildenafil citrate. Drugs Today (2000) 36:125–134.
   PubMed Web of Science ®Google Scholar
• MITKA M: Some men who take VIAGRA die - why? JAMA (2002) 283:590–591.
   Web of Science ®Google Scholar
• NELSON RP, BARADA JH, COSTABILE RA et al.: Does renewed sexual activity increase cardiac morbidity? Meta-analysis of the experience with MUSETM. I Urol. (1999) 161(4, Suppl.):215.
   Google Scholar
• COHEN JS: Comparison of FDA reports of patient death associated with sildenafil and with injectable alprostadil. Ann. Pharmacother. (2001) 35:285–288.
   PubMed Web of Science ®Google Scholar
• GEELEN P, DROLET B, RAIL J et al.: Sildenafil (VIAGRA) prolongs cardiac repolarization by blocking rapid component of the delayed rectifier potassium current. Circulation (2000) 102:275–277.
   PubMed Web of Science ®Google Scholar
• ISHIKURA F, BEPPU S, HAMADA T, KHANDHERIA BK, SEWARD JH: Effects of sildenafil citrate (VIAGRA) combined with nitrate on heart. Circulation (2000) 102:2516–2521.
   PubMed Web of Science ®Google Scholar
• STIEF CG, OCKERT S, BECKER AJ et al.: Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology (2000) 55:146–150.
   PubMed Web of Science ®Google Scholar
• CONTI CR, PEPINE CJ, SWEENEY M:Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am. J. Cardiol (1999) 83:29C–34C.
   Google Scholar
• ZUSMAN RM, MORALES A, GLASER DB, OSTERLOH IA: Overall cardiovascular profile of sildenafil citrate. Am. J. Cardiol (1999) 83:35C–44C.
   Google Scholar
• SAENZ DE TEJADA I, ANGULO J, CUE VAS P et al.: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res. (2001) 13:282–290.
   Google Scholar
• BISCHOFF E, MONDRITZKI T, NIEWOEHNER U, HANING A, ZIMMER D: Vardenafil improved erections in rabbits longer than expected from plasma half-life. Int. .1. Impot. Res. (2002) 14\(Suppl. 4):542.
   Google Scholar
• YOUNG J, AUERBACH S, PORST H: Vardenafil, a new selective PDE5 inhibitor, significantly improved all IIEF domains and showed favourable safety profile in patients with erectile dysfunction over 12 weeks. Urol. (2001) 165(5, Suppl.):224.
   Google Scholar
• GOLDSTEIN I, YOUNG J, FISCHER J: Vardenafil: a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes (2001) 513\(Suppl. 2):A114.
   Google Scholar
• BROCK G, PADMA-NATHAN H, SEGER M: Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Ear. Urol. (2002) l\(Suppl. 1):152.
   Google Scholar
• MAZZU A, NICHOLLS A, ZINNY M: Vardenafil: a new highly selective PDE5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged subjects. hat. Impot. Res. (2001) 13\(Suppl. 5):564.
   Google Scholar
• THADANI U, MAZZU A: Exercise-induced ischemia was not adversely affected by vardenafil during exercise stress test in men with coronary artery disease. Ear: Urol. (2002) l\(Suppl. 1):151.
   Google Scholar
• EARDLY I, CARTLEDGE J: Tadalafil (CIALIS) for men with erectile dysfunction. hat. Clin. Pract. (2002) 56:300–304.
   PubMed Web of Science ®Google Scholar
• YUASA K, KOTERA J, FUJISHIGE K, MICHIBATA H, SASAKI T, OMORI K: Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression." Biol. Chem. (2000) 275:31469–31479.
   PubMed Web of Science ®Google Scholar
• BROCK GB, MCMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. Urol. (2002) 168:1332–1336.
   Web of Science ®Google Scholar
• GUILIANO F, VARANESE L: Tadalafil: a novel treatment for erectile dysfuncion. Ear. Heart J. (2002) 4(Suppl. H):H24–H31.
   Google Scholar
• GEBEKOR E, BETHELL S, FAWCETT L: Selectivity of sildenafil and other phosphodiesterase Type 5 inhibitors against all human phosphodiesterase families. Ear: Urol. (2001) l\(Suppl. 1):63.
   Google Scholar
• EMMICK JT, STUEWE SR, MITCHELL M: Overview of the cardiovascular effects of tadalafil. Ear: Heart .1. (2002) 4(Suppl. H):H32–H47.
   Google Scholar
• ANDERSSON K-E, STIEF CG: Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms. Am. J. Cardiol (2000) 86(Suppl.):23F–26F.
   Google Scholar
• COTZIAS GC, VAN WOERT MH, SCHIFFER LM: Aromatic amino acids and modification of parkinsonism. N Engl. J. Med. (1967) 276:374–379.
   PubMed Web of Science ®Google Scholar
• LAL S: Apomorphine in the evaluation of dopaminergic function in man. Frog. Neuropsychopharmacol Biol. Psychiatry (1988) 12:117–164.
   PubMed Web of Science ®Google Scholar
• RAMPIN 0: Mode of action of a new oral treatment for erectile dysfunction: apomoprhine SL. BJUInt. (2001) 88\(Suppl. 3):22–24.
   Google Scholar
• OCKERT S, BECKER AJ, NESS BO et al: Oxytocin plasma levels in the systemic and cavernous blood of healthy males during different penile conditions. World J. Urol. (2003) 20:323–326.
   PubMed Web of Science ®Google Scholar
• BURS RM: Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res. (1978) 192:423–435.
   PubMed Web of Science ®Google Scholar
• MELIS MR, ARGIOLAS A: Nitric oxide synthase inhibitors prevent apomorphine-and oxytocin-induced penile erection and yawning in male rats. Brain Res. Bull. (1993) 32:71–74.
   PubMed Web of Science ®Google Scholar
• STIEF CG, PADLEY RJ, PERDOK RJ, SLEEP DJ: Cross-study review of the clinical efficacy of Apomorphine SL 2 and 3 mg: pooled data from the three placebo-controlled, fixed-dose crossover studies. Ear. Urol. (2002) 1(3, Suppl.):12–20.
   Google Scholar
• BUVAT J, MONTORSI F: Safety and tolerability of Apomorphine SL in patients with erectile dysfunction. BIU Int. (2001) 88\(Suppl. 3):30–35.
   Google Scholar
• REHMAN J, KAYNAN A, CHRIST G, VALCIC M, MAAYANI S, MELMAN A: Modification of sexual behaviour of Long-Evans male rats by drugs acting on the 5-HTja receptor. Brain Res. (1999) 821:414–425.
   PubMed Web of Science ®Google Scholar
• TANGY, RAMPIN 0, CALAS A, FACCHINETTI P, GUILIANO F: Oxytocinergic and serotonergic innervation of identified lumbosacral nuclei controlling penile erection in the male rat. Neuroscience (1998) 82:241–254.
   PubMed Web of Science ®Google Scholar
• WITT MA, GRANTMYRE JE: Ejaculatoryfailure. World J. Ural. (1993) 11:89–95.
   PubMed Web of Science ®Google Scholar
• SVENSSON L, HANSEN S: Spinal monoaminergic modulation of masculine copulatory behaviour in the rat. Brain Res. (1984) 302:315–321.
   PubMed Web of Science ®Google Scholar
• GORZALKA BB, MENDELSON SD, WATSON NV: Serotonin receptor subtypes and sexual behaviour. Ann. NY Acad. Sci. (1990) 600:445–446.
   Google Scholar
• AIZENBERG D, GUR S, ZEMISHLANY Z, GRANEK M, JECZMIEN P, WEIZMAN A: Mianserin, a 5-HT2a/2c and alpha2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin. Neuropharmacol (1997) 20:210–214.
   PubMed Web of Science ®Google Scholar
• OCKERT S, FUHLENRIEDE MH, BECKER AJ, STIEF CG, JONAS U: Is there a significance of serotonin in the control of penile flaccidity and detumescence in the human male? hat. J. Impot. Res. (2002) 14\(Suppl. 4):540–541.
   Google Scholar
• LAL S, RIOS 0, THAVUNDAYIL JX: Treatment of impotence with trazodone: a case report." Urol. (1990) 143:819–820.
   Google Scholar
• ADAIKAN PG, NG SC, CHAN C, RATNAM SS: Oral trazodone in the treatment of total secondary impotence in a diabetic patient. Br. J. Urol. (1991) 63:771–772.
   Google Scholar
• HORBY-PETERSEN J, NIELSEN FC, SCHMIDT PF: Penile tumescence after injection of a serotonin antagonist (ketanserin). Br. J. Urol. (1988) 62:277–278.
   PubMedGoogle Scholar
• KURT 0, OZKARDES H, ALTUG U, GERMIYANOGLU C, GORDAL M, EROL D: The efficacy of anti-serotonergic agents in the treatment of erectile dysfunction.' Urol. (1994) 152:407–409.
   PubMed Web of Science ®Google Scholar
• DENNINGER JW, MARLETTA MA: Guanylate cyclase and the NO/cGMP signalling pathway. Biochim. Biophys. Acta (1999) 1411:334–350.
   PubMed Web of Science ®Google Scholar
• LEE YC, MARTIN E, MURAD F: Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc. Natl. Acad. Sci. USA (2000) 97:10763–10768.
   PubMed Web of Science ®Google Scholar
• HOBBS AJ: Soluble guanylate cyclase: anold therapeutic target re-visited. Br. J. Pharmacol (2002) 136:637–640.
   PubMed Web of Science ®Google Scholar
• FRIEBE A, MOLLERSHAUSEN F, SMOLENSKI A, WALTER U, SCHULTZ G, KOESLING D: YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. MM. Pharmacol (1998) 54:962–967.
   PubMed Web of Science ®Google Scholar
• MIZUSAWA H, HEDLUND P, BRIONI JD, SULLIVAN JP, ANDERSSON K-E: Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. Urol. (2002) 167:2276–2281.
   Web of Science ®Google Scholar
• NAKANE M, HSIEH G, MILLER LN et al.: Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int. J. In-1pm. Res. (2002) 14:121–127.
   Google Scholar
• BISCHOFF E, SCHRAMM M, STRAUB A, FEURER A, STASCH JP: BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide dependent penile erection. Urology (2003) 61:464–467.
   PubMed Web of Science ®Google Scholar
• STRAUB A, STASCH JP, ALONSO-ALIJA C et al.: NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. (2001) 11:781–784.
   PubMed Web of Science ®Google Scholar
• STASCH JP, DEMBOWSKY K, PERZBORN E, STAHL E, SCHRAMM M: Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41–8543: in vivo studies. Br: J. Pharmacol (2002) 135:344–355.
   Google Scholar
• STASCH JP, ALONSO-ALIJA C, APELER H et al.: Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41–8543: M vitro studies. Br: J. Pharmacol (2002) 135:333–343.
   Google Scholar
• MORELAND RB, HSIEH GC, NAKANE Metal: Novel soluble guanylate cyclase activators A-344905 and A-305619 activate sGC in vitro and facilitate penile erection in rats. J. Urol. (2002) 167(4, Suppl.):S938.
   Google Scholar
• MILLER LN, NAKANE M, HSIEH GC et al.: A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. (2003) 72:1015–1025.
   PubMed Web of Science ®Google Scholar
• SEIDLERM, OCKERT S, WALDKIRCH E et al: In vitro effects of a novel class of nitric oxide (NO)-donating compounds on isolated human erectile tissue. Eut: Urol. (2002) 42:523–528.
   PubMed Web of Science ®Google Scholar
• RIFFAUD JP, BERNARBE J, GIULIANO F, JONES R, JEREMY J: Pharmacological profile of sildenafil nitrate (NCX 911) in various models of penile erection. Inflammation Res. (2001) 50\(Suppl. 3):584.
   Google Scholar
• KUENSCH E, REINERS K, MOLLER-MATTHEIS V, STROHMEYER T, ACKERMANN R, FREUND H-J: Neurological risk profile in organic erectile dysfunction. J. Nemo]. Neurosurg. Psych. (1992) 55:275–281.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, OCKERT S, STIEF CG et al.: Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy males and patients with erectile dysfunction. Urology (2002) 59:281–286.
   PubMed Web of Science ®Google Scholar
• KRANE RJ, GOLDSTEIN I, SAENZ DE TEJADA I: Medical progress: Impotence. N. Engl. J. Med. (1989) 321:1648–1659.
   PubMed Web of Science ®Google Scholar
• WAGNER G, LACY S, LEWIS R, ZORGNIOTTI A: Buccal phentolamine - a pilot trial for male erectile dysfunction at three separate clinics. Int. J. Impot. Res. (1994) 6\(Suppl. 1):D78.
   Google Scholar
• TRAISH A, GUPTA S, GALLANT C, HUANG YH, GOLDSTEIN I: Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int. .1. Impot. Res. (1998) 10:215–223.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN I,VASOMAX STUDY GROUP: Efficacy and safety of oral phentolamine (VASOMAX) for the treatment of minimal erectile dysfunction. Urol. (1998) 159(Suppl.):240.
   Google Scholar
• GOLDSTEIN I: First-line therapy: Alpha-adrenergic receptor antagonists - clinical. Masters Course in Erectile Dysfunction, Boston MA, USA (1999) (Podium presentation).
   Google Scholar
• BORG KE, ESBENSHADE KL, JOHNSON BH: Cortisol, Growth hormone, and testosterone concentrations during mating behaviour in bulls and boars. J. Amin. Sci. (1991) 69:230–240.
   Google Scholar
• PENSON DF, NG C, RAJFER J, GONZALES-CAVIDAD NF: Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology (1997) 138:3925–3932.
   PubMed Web of Science ®Google Scholar
• ARGIOLAS A, MELIS MR, GESSA GL: Yawning and penile erection: central dopamine - oxytocin - adrenocorticotropin connection. Ann. NY Acad. Sci. (1988) 525:330–337.
   PubMed Web of Science ®Google Scholar
• VERGONI AV, BERTOLINI P, MUTULIS F, WIKBERG JE, SCHIOTH HB: Differential influence of a selective melanocortin MC4 receptor antagonist (H5014) on melanocortin-induced behavioural effects in rats. Eut: Pharmacol (1998) 362:95–101.
   PubMed Web of Science ®Google Scholar
• BRETTO LA, GORZALKA BB: Melatonin enhances sexual behaviour in the male rat. Physiol Behav. (2000) 68:483–486.
   PubMed Web of Science ®Google Scholar
• MOUNTJOY KG, ROBBINS LS, MORTRUD MT, CONE RD: The cloning of a familiy of genes that encode the melanocortin receptors. Science (1992) 257:1248–1251.
   PubMed Web of Science ®Google Scholar
• VAN DER KRAAN M, ADAN RA, ENTWISTLE ML, GISPEN WH, BURBACH JP, TATRO JB: Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology (1998) 139:2348–2355.
   PubMed Web of Science ®Google Scholar
• ISIDORI A, DI LUIGI L, CONTE D: ACTH 1-17 and sexual behaviour. Ric. Clin. Lab. (1984) 14:247–251.
   PubMedGoogle Scholar
• WESSELLS H, FUCIURELLI K, HANSEN J et al: Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: a double-blind, placebo-controlled crossover study. J. Un]. (1998) 160:389–393.
   Google Scholar
• WESSELLS H, LEVINE N, HADLEY ME, DORR R, HRUBY VJ: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int. J. Impot. Res. (2000) 12 (Suppl. 4):574–579.
   Google Scholar
• LEVINE N, SHEFTEL SN, EYTAN T et al.: Induction of skin tanning by subcutaneous adminstration of a potent synthetic melanotropin. JA/VIA (1991) 266:2730–2736.
   Web of Science ®Google Scholar
• HULL KL, HARVEY S: Growth hormone:a reproductive endocrine-paracrine regulator. Rev Reprod. (2000) 5:175–182.
   PubMedGoogle Scholar
• CHANDRASHEKAR V, BARTKE A: The role of growth hormone in the control of gonadotropin secretion in adult male rats. Endocrinology (1998) 139:1067–1074.
   PubMed Web of Science ®Google Scholar
• JUUL A, ANDERSSON AM, PEDERSEN SA et al.: Effects of growth hormone replacement therapy on IGF-related parameters and on pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study. Dorm. Res. (1998) 49:269–278.
   Google Scholar
• JUNG GW, SPENCER EM, LUE TF: Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats. J. Un]. (1998) 160:1899–1904.
   Google Scholar
• BOGER RH, SKAMIRA C, BODE-BOGER SM, BRABANT EG, VON ZUR MOHLEN A, FROLICH JC: Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. Clin. Invest. (1996) 98:2706–2713.
   Google Scholar
• BECKER AJ, OCKERT S, STIEF CG et al.: Possible role of human growth hormone in penile erection. Urol. (2000) 164:2138–2142.
   Web of Science ®Google Scholar
• BECKER AJ, OCKERT S, STIEF CG et al: Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology (2002) 59:609–614.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, OCKERT S, STIEF CG, JONAS U: Growth hormone, somatomedins and men's health. Aging Male (2002) 5:258–262.
   PubMedGoogle Scholar
• RUDMAN D, FELLER AG, NAGRAJ HS et al.: Effects of growth hormone in men over 60 years old. N Engl. Med. (1990) 323:1–6.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS MA, GRADY D, BLACK D et al: Growth hormone replacement in older men improves body composition but not functional ability. Ann. Intern. Med. (1996) 124:708–716.
   PubMed Web of Science ®Google Scholar
• JEFFCOATE W: Can growth hormone therapy cause diabetes? Lancet (2000) 355:589–590.
   Google Scholar
• MONSON JP, BENGTSSON BA, ABS R, FELDT-RASMUSSEN U, WOSTER C: Can growth hormone therapy cause diabetes? Letter to the Editor. Lancet (2000) 355:1728.
   PubMed Web of Science ®Google Scholar
• CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science (1998) 279:563–566.
   PubMed Web of Science ®Google Scholar
• ZORGNIOTTI AW, LIZZA EF: Effect of large doses of the nitric oxide precursor L-arginine on erectile dysfunction. Int. Impot. Res. (1994) 6:33–35.
   PubMedGoogle Scholar
• HO GD, SILVERMAN L, BERCOVICI A et al.: Synthesis and evaluation of potent and selective cGMP-phosphodiesterase inhibitors. Bioorg. Med. Chem. Lett (1999) 9:7–12.
   PubMed Web of Science ®Google Scholar
• ROTELLA DP, SUN Z, ZHU J et al: Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.Med. Chem. (2000) 43:5037–5043.
   Web of Science ®Google Scholar
• GUAY D, HAMEL P, BLOUIN Metal: Discovery of L-791.943: a potent, selective, non-emetic and orally active phosphodiesterase 4 inhibitor. Bioorg. Med. Chem. Lett. (2002) 12:1457–1461.
   Google Scholar